Home › Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital
 

Keywords :   


Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital

2015-06-06 21:12:59| Biotech - Topix.net

REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray reiterated a "neutral" rating and set a $484.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 21st.

Tags: rating capital pharmaceuticals rbc

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Tropical Storm Joyce Wind Speed Probabilities Number 7
29.09Tropical Storm Joyce Forecast Discussion Number 7
More »